37746-82-0

Usage

Uses

Used in Chemical Synthesis:
(2E)-4,4-Difluoro-2-butenoic acid ethyl ester is used as an intermediate in the synthesis of various chemical compounds, particularly in the preparation of β-fluoroalkyl acrylates from fluoroacetic esters. Its unique fluorinated structure allows for the creation of new molecules with specific properties, making it a valuable component in the development of novel chemical products.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, (2E)-4,4-Difluoro-2-butenoic acid ethyl ester may be utilized as a building block for the development of new drugs with potential therapeutic applications. Its fluorinated nature can contribute to the enhancement of drug properties, such as bioavailability, metabolic stability, and target specificity.
Used in Material Science:
(2E)-4,4-Difluoro-2-butenoic acid ethyl ester can also be employed in the field of material science for the development of new materials with specific properties. Its fluorinated structure may contribute to the creation of materials with improved chemical resistance, thermal stability, or other desirable characteristics.

Upstream product

• 145374-00-1 ethyl 4,4-difluoro-3-hydroxy-butanoate 
• 352-24-9 ethyl 4,4-difluoro-3-oxobutyrate 
• 64-17-5 ethanol 
• 37759-73-2 (E)-4,4-difluoro-but-2-enoic acid 

Downstream Products

• 37759-73-2 (E)-4,4-difluoro-but-2-enoic acid 

Relevant academic research and scientific papers

CARBOXAMIDES AS UBIQUITIN-SPECIFIC PROTEASE INHIBITORS

The present disclosure relates to modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25, pharmaceutical compositions comprising the inhibitors, and methods of using the inhibitors. The modulators, such as inhibitors, of at least one pathway chosen from USP28 and USP25 can be useful in the treatment of cancers, among other ailments.

PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS

The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where m, n, X1, X2, R1-R5, R5′ and R6 are described herein.

IMPROVED PROCESS FOR PREPARING SUBSTITUTED CROTONIC ACIDS

A process to prepare a compound of Formula (I) wherein R3, R4 and R5 are each selected independently from hydrogen, halogen, alkyl, alkenyl, alkynyl, alkoxyl, and wherein the alkyl, alkenyl, alkynyl, and alkoxyl may be optionally substituted with one or more halogen, alkyl, alkenyl, alkynyl, and alkoxyl.

BRUTON'S TYROSINE KINASE INHIBITORS

Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (BTK). Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the BTK inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions. (Formula I)

Studies on a three-step preparation of β-fluoroalkyl acrylates from fluoroacetic esters

β-Fluoroalkyl-acrylic esters are valuable building blocks for the synthesis of organofluorine compounds. Although the preparation of several β-fluoroalkyl-acrylates is known, a general and straightforward lab-scale methodology for the preparation of multigram amounts of these compounds from fluoroacetic esters is not available, and the related chemistry has not been investigated in detail. We now describe an optimized three-step protocol relying on: (1) Claisen-type condensation of fluoroacetic esters with ethyl acetate, using LDA as base; (2) reduction of the resulting γ-fluoro-β-keto esters by NaBH4, using toluene or benzene as solvents; (3) P2O5-promoted dehydration of the intermediate γ-fluoro-β-hydroxy esters. The methodology affords preparatively useful yields of the target compounds incorporating only fluorine atoms (CF3, CHF2, C2F5), whereas the γ-halodifluoromethyl (CClF2, CBrF2, CIF2) acrylates could not be obtained in analytically pure form from the dehydration step.